Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  irinotecan hydrochloride
Find trials that include:  Any drugs shown
Results 1-25 of 66 for your search:
Start Over
Risk-Based Therapy in Treating Younger Patients with Newly Diagnosed Liver Cancer
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 21 and under
Trial IDs: AHEP0731, NCI-2011-01975, CDR0000654889, COG-AHEP0731, NCT02265692, PAHEP0731_A08PAMDREVW01, NCT00980460
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: NLG0505, NCI-2013-01044, 1210-1195, NCT01836432
Combination Chemotherapy with or without Stereotactic Body Radiation Therapy in Treating Patients with Locally Advanced Pancreatic Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: PANC0015, NCI-2013-01658, 5136, NCT01926197
Irinotecan Hydrochloride With or Without Ascorbic Acid in Treating Patients With Stage IV Colorectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11D.459, NCI-2012-00310, 2011-62, NCT01550510
Study of MLN8237 in Combination With Irinotecan and Temozolomide
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 30
Trial IDs: N2009-03, NCI-2015-00834, NCT01601535
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLJM716X2103, NCI-2013-01355, NCT01822613
DNA Methyltransferase Inhibitor SGI-110 and Irinotecan Hydrochloride or Regorafenib Alone in Treating Patients with Previously Treated Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NA_00085870, J1369, NCI-2013-02005, CIR00004735, CIR0002117, NA_00085870, NCT01896856
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
S1313, Combination Chemotherapy with or without PEGPH20 in Treating Patients with Newly Diagnosed Metastatic Pancreatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: S1313, NCI-2013-01776, NCT01959139
WEE1 inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients with Relapsed or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1312, NCI-2014-00547, NCT02095132
Gemcitabine Hydrochloride, Docetaxel, Capecitabine, Cisplatin, and Irinotecan Hydrochloride in Treating Patients with Metastatic Pancreatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 76
Trial IDs: J14161, NCI-2015-00235, NCT02324543
Neoadjuvant GMCI Plus mFOLFIRINOX and Chemoradiation for Non-Metastatic Pancreatic Adenocarcinoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 76
Trial IDs: PaTK02, NCI-2015-00859, NCT02446093
Irinotecan Hydrochloride and Panitumumab as Second-Line Therapy in Treating Patients With Locally Recurrent or Metastatic Esophageal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: 07-161, NCI-2011-02478, NCT00836277
Erlotinib Hydrochloride and Panitumumab with or without Irinotecan Hydrochloride as Second Line Therapy in Patients with Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 07I4, NCI-2011-00222, OSI 4263s, NCT00940316
Temozolomide and Irinotecan Hydrochloride with or without Bevacizumab in Treating Young Patients with Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: ACNS0821, NCI-2011-02605, CDR0000686608, COG-ACNS0821, NCT01217437
Combination Chemotherapy with or without Regorafenib in Treating Patients with Metastatic Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LCCC 1029, NCI-2013-00954, 10-2176, NCT01298570
Combination Chemotherapy with or without Panitumumab in Treating Patients with Colorectal Cancer with Liver Metastases Previously Treated with Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-137, NCI-2011-00375, NCT01312857
Combination Chemotherapy in Treating Patients With Advanced or Metastatic Pancreatic Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 1108008901, NCI-2012-00158, NCT01523457
Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Patients with High-Risk Pancreatic Cancer That Can Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2011-1208, NCI-2012-00571, NCT01560949
Combination Chemotherapy and Radiation Therapy before Surgery in Treating Patients with Pancreatic Cancer That May Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-328, NCI-2012-01540, NCT01591733
Irinotecan Hydrochloride in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INST 1201, NCI-2012-01531, NCT01607554
Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients with Pancreatic Cancer That May Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2011.007, NCI-2012-01916, HUM00047389, HUM 47389, NCT01661088
Combination Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1105, NCI-2013-01059, NCT01688336
Irinotecan Hydrochloride and Temozolomide with Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients with Refractory or Relapsed Neuroblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Children
Trial IDs: ANBL1221, NCI-2012-03125, CDR0000745188, COG-ANBL1221, NCT01767194
Start Over